EnChannel Medical raised $82.2M in Series B financing, co-led by Dragonball Capital and Lilly Asia Ventures, to accelerate product development and advance clinical trials.
EnChannel Medical raised $82.2M in Series B financing, co-led by Dragonball Capital and Lilly Asia Ventures, to accelerate product development and advance clinical trials.
05/01/25, 11:14 AM
Location
guangzhouMoney raised
$82.2 million
Industry
medical
biotechnology
health care
Round Type
series b
Investors
Lapam Capital, Lilly Asia Ventures, Dragonball Capital
EnChannel Medical, based in Guangzhou, China, closed a Series B financing round, raising $82.2M. The funding will support product development and clinical registration trials globally. The round was co-led by Dragonball Capital and Lilly Asia Ventures. Founded in 2020, EnChannel focuses on innovations in cardiac electrophysiology.
Company Info
Location
guangzhou, guangdong province, china
Additional Info
EnChannel Medical is an innovator in cardiac electrophysiology, developing a holistic platform for personalized treatment of atrial fibrillation. Founded in 2020, the company is led by seasoned electrophysiology experts and aims to unify several advanced technologies in cardiac treatment. The company has secured significant funding to enhance product development and clinical trials worldwide. EnChannel is headquartered in Guangzhou, China, with an R&D subsidiary in Irvine, California.